Skip to content

Veradermics MANE Net Income

Net Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.24B-52.4%
Hims & Hers Health logo
Hims & Hers HealthHIMS
-$92.12M-286%
Organon logo
OrganonOGN
$146M+67.8%
PVL
Palvella TherapeuticsPVLA
-$15.77M-92.6%
TTR
Turn Therapeutics Inc.TTRX
-$970.97K-196%
PTH
Pelthos Therapeutics Inc.PTHS
-$10.24M-420%

Segments

By segment

See full
Reportable Segment-$27.23M-120%

Other financials

Income statement

See full
Operating income-$29.9M-131%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$5.22B+315%

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's net income?
Veradermics (MANE) reported net income of -$27.23M in Q1 2026.
How has Veradermics 's net income changed year-over-year?
Veradermics 's net income decreased by 119.6% year-over-year, from -$12.4M to -$27.23M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.